<DOC>
	<DOCNO>NCT00557739</DOCNO>
	<brief_summary>CRx-191 proprietary synergistic combination drug candidate evaluate CombinatoRx topical psoriasis therapy . CRx-191 identify via proprietary screen assay novel drug combination demonstrate enhanced inhibition tumor necrosis factor- alpha interferon-gamma release , cytokine implicate pathogenesis psoriasis . This clinical trial ass effectiveness CRx-191 reduce psoriatic infiltrate band thickness measure transdermal ultrasound . All subject receive treatment separate test field , intra-individual comparison treatment .</brief_summary>
	<brief_title>Study CRx-191 Assess Activity Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<criteria>Subject must voluntarily give write informed consent Subject must 18 70 year age Subject must chronic plaque psoriasis stable plaque area sufficient six treatment field The physical examination must without disease finding unless investigator considers abnormality irrelevant outcome study Sexually active female childbearing potential either surgically sterile ( hysterectomy tubal ligation ) , use highly effective medically accept contraceptive regimen Erythrodermic , guttate pustular psoriasis Cardiac disease , include recent myocardial infarction , degree heart block cardiac arrhythmia valvular heart disease Mania Narrow angle glaucoma Hyperthyroidism medical history , thyroid stimulate hormone ( TSH ) less low limit normal ( LLN ) , receive thyroid medication Intolerance Lidocaine Severe liver disease ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) laboratory value exceed 1.5x upper limit normal ( ULN ) ) Inflammatory dermatoses except psoriasis ; bacterial , viral fungal skin infection ; facial rosacea Active varicella , tuberculosis , syphilis postvaccine reaction Autoimmune disease plaque psoriasis ( e.g . lupus erythematosis psoriatic arthritis ) Known allergic reaction hypersensitivity component study preparation Allergy adhesives hydrocolloid dress use study UV therapy four week study History malignancy ( except treat excised basal cell carcinoma ) Surgery within previous 3 month ( except minor cosmetic dental procedure ) History drug alcohol abuse ( define Investigator ) Symptoms clinically significant illness four week study may influence outcome study Positive HIV antibody Subjects require systemically acting medication treatment psoriasis might counter influence study objective : Methotrexate ; Cyclosporine ; AntiTNFÎ± therapies Subjects require medication inhibit CYP450 2D6 pathway : Quinidine ; Cimetidine ; Type 1 antiarrhythmic ; Phenothiazines ; Selective serotonin reuptake inhibitor fluoxetine , paroxetine , sertraline ; Reserpine , anticholinergic drug , sympathomimetic drug Topical treatment psoriasis ( except salicylic acid vaseline ) four week precede study ( topical corticosteroid disallow eight week prior study ) Systemic treatment two week precede study may interact study drug , : Glucocorticoids ( po , im , iv ) ; MAO inhibitor ; Antidepressants ; Antiseizure medication ; Antipsychotics ; Antihistamines Treatments two week precede study may aggravate psoriasis , : Antimalarials ; Betablockers Participation another clinical trial and/or treatment receive investigational agent within one month initial dose study medication Female subject pregnant lactating Significant UV exposure four week study Unwilling unable comply requirement protocol , include presence condition ( physical , mental , social ) likely affect subject 's return followup visit schedule Other unspecified reason , opinion Investigator sponsor make subject unsuitable enrollment Subject institutionalized legal regulatory order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>CRx-191</keyword>
	<keyword>Plaque</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>nortriptyline hydrochloride</keyword>
	<keyword>mometasone furoate</keyword>
	<keyword>psoriatic infiltrate</keyword>
</DOC>